2026
conference-abstract
OpenAlex
Robert Saddawi-Konefka, H.W. Wang, Lauren M. Clubb, Cynthia Y. Tang et autres
Abstract Immune checkpoint inhibition (ICI) has emerged as a pivotal therapy for head and neck squamous cell carcinoma (HNSCC), yet the development of predictive biomarkers to guide its clinical application has significantly lagged. Current biomarkers such as tumor mutational burden and PD-L1 …
us, my
(code pays fourni par la source)
Accès ouvert
2025
conference-paper
OpenAlex
Robert Saddawi‐Konefka, Riyam Al Msari, Shiqi Tang, Sayed Sadat et autres
Background The phase III trial KEYNOTE-689 has now established a new standard of care in resectable, locally advanced head and neck squamous cell carcinoma by integrating perioperative PD-1 blockade with surgery and (chemo)radiation. In contrast, four recent phase III trials adding concurrent …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Binbin Wang, Robert Saddawi‐Konefka, Lauren M. Clubb, Shiqi Tang et autres
Immune checkpoint blockade (ICB) has improved outcomes for patients with head and neck squamous cell carcinoma (HNSCC), but predictive biomarkers remain limited. Here, we use a time-resolved, multi-omic approach in a murine HNSCC model to characterize peripheral immune responses to ICB. Single-cell …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Robert Saddawi‐Konefka, Riyam Al Msari, Shiqi Tang, Sayed Sadat et autres
Surgical ablation or broad radiation of tumor-draining lymph nodes can eliminate the primary tumor response to immunotherapy, highlighting the crucial role of these nodes in mediating the primary tumor response. Here, we show that immunoradiotherapy efficacy is dependent on treatment sequence and …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Binbin Wang, Robert Saddawi‐Konefka, Lauren M. Clubb, Shiqi Tang et autres
Abstract Background & Approach: Immune checkpoint blockade (ICB) therapy has shown promise for head and neck squamous cell carcinoma (HNSCC); however, response rates remain limited, with only a subset of patients exhibiting significant clinical benefits. Identifying non-invasive liquid biomarkers to predict ICB …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Robert Saddawi‐Konefka, Riyam Al Msari, Cynthia Y. Tang, Sayed Sadat et autres
Abstract Immune checkpoint inhibition has demonstrated no benefit when combined with chemoradiotherapy for locally advanced HNSCC, raising the possibility that standard therapies compromise the response to immunotherapy. We previously demonstrated that ablating tumor draining lymphatics abolishes the response to immune-oncology therapy. Specifically, …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Robert Saddawi‐Konefka, Riyam Al Msari, Shiqi Tang, Lauren M. Clubb et autres
Abstract Immune checkpoint inhibition has demonstrated no benefit when combined with chemoradiotherapy for locally advanced HNSCC, raising the possibility that standard therapies compromise the response to immunotherapy. To address this hypothesis, we previously demonstrated that ablating tumor draining lymphatics abolishes the response …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Robert Saddawi‐Konefka, Riyam Al Msari, Shiqi Tang, Lauren M. Clubb et autres
Abstract Immune checkpoint inhibition has demonstrated no benefit when combined with chemoradiotherapy for locally advanced HNSCC, raising the possibility that standard therapies compromise the response to immunotherapy. To address this hypothesis, we previously demonstrated that ablating tumor draining lymphatics abolishes the response …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Farhoud Faraji, Sydney I. Ramirez, Lauren M. Clubb, Kuniaki Sato et autres
Tumor initiation represents the first step in tumorigenesis during which normal progenitor cells undergo cell fate transition to cancer. Capturing this process as it occurs in vivo, however, remains elusive. Here we employ spatiotemporally controlled oncogene activation and tumor suppressor inhibition together …
us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Robert Saddawi‐Konefka, Yujie Shi, Shiqi Tang, Lauren M. Clubb et autres
Background Head and neck squamous cell carcinomas (HNSCCs) represent the sixth most common cancer worldwide with an estimated 65,630 cases and 14,500 deaths in the United States last year. Fortuitously, by virtue of their high mutational burden and robust neoantigenome, HNSCCs harbor …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Chakit Arora, Marin Matic, Luisa Bisceglia, Pierluigi Di Chiaro et autres
We explored the dysregulation of G-protein-coupled receptor (GPCR) ligand systems in cancer transcriptomics datasets to uncover new therapeutics opportunities in oncology. We derived an interaction network of receptors with ligands and their biosynthetic enzymes. Multiple GPCRs are differentially regulated together with their …
it, us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Robert Saddawi‐Konefka, Riyam Al Msari, Lauren M. Clubb, Shiqi Tang et autres
Background PD-1 inhibition (PD1i) has demonstrated no benefit for locally advanced HNSCC, and emerging neoadjuvant PD1i window of opportunity trial data yield promising but limited responses. Our previous work demonstrates that ablating tumor draining lymphatics compromises the response to immune-oncology therapy.1 In …
us
(code pays fourni par la source)